Skip to main content

Table 3 Clinical characteristics of the patients with RA from the first and second replication collections

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

 

First replication

Second replication

Features

All patients

Infliximab

Adalimumab

Infliximab

Patients, number (%)

404

199 (49.3)

205 (50.7)

386

Female (%)

77.2

77.9

76.6

89.1

Age at diagnosis, median (IQR)

46 (34 to 53)

42 (33 to 51)

48 (36 to 56)

44 (35 to 51)

Diagnosis to anti-TNF, median (IQR)

10 (5 to 17)

11 (6 to 18)

9 (4 to 17)

8 (4 to 15)

ACPA, %a

77.4

79.4

75.5

60.9

Erosive arthritis, %a

58.2

65.0

51.1

77.6

Smoking, %a

56.6

56.8

56.3

26.1

Concomitant DMARDs (%)a

100

100

100

96.4

Baseline HAQ, median (IQR)

2.0 (1.6 to 2.4)

2.0 (1.8 to 2.5)

2.0 (1.5 to 2.3)

1.9 (1.4 to 2.3)

DAS28, (mean ± SD)

    

 baseline

6.5 ± 1.1

6.7 ± 1.0

6.3 ± 1.1

6.1 ± 1.2

 six months

4.1 ± 1.3

4.3 ± 1.3

3.8 ± 1.2

4.1 ± 1.5

six months EULAR response, %

    

 responder

21.3

17.1

25.4

29.2

 moderate

69.6

73.4

65.9

46.9

 no-responder

9.2

9.5

8.8

24.0

  1. aData from <85% of patients: in the first replication (310 patients for concomitant DMARDs); in the second replication (196 patients for erosive arthritis; 174 for ACPA; 115 patients for smoking). ACPA, anti-citrullinated peptide antibodies; ADM, adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity score in 28 joints; DMARDs, disease modifying antirheumatic drugs; EULAR, European League against Rheumatism; HAQ, Health Assessment Questionnaire; INX, infliximab; IQR, interquartile range; RA, rheumatoid arthritis; SD, standard deviation.